Currently, Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and the BCL-2 inhibitor venetoclax are clinical MCL treatment options that produce high response rates and reasonably durable outcomes in this patient population10–12. The gene discussed is BCL2; the disease is mantle cell lymphoma.